Brief: Antisense Therapeutics Announces Long COVID-19 Strategic Collaboration With U.S. Experts
Feb 24 (Reuters) - Antisense Therapeutics Ltd ANP.AX :
* ANNOUNCES SIGNING OF DEAL & START OF COLLABORATION TO
STUDY
NEUROLOGICAL ASPECTS OF LONG COVID-19 WITH U.S. BASED
RESEARCHERS
Source text for Eikon: ID:nASX5dQx2K
Further company coverage: ANP.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Percheron Therapeutics
See all newsBrief: Invion Announces Preclinical Research Collaboration With Percheron Therapeutics
Brief: Percheron Therapeutics Receives Firm Commitments For A$2.3 Million Institutional Placement
Brief: Percheron Therapeutics Appoints Ambrosini as Interim Board Member During CEO Transition Period
Brief: Percheron Therapeutics Says Vanderbilt Health To Conduct Clinical Trial Of Hmbd-002 In Acute Myeloid Leukaemia
Brief: Percheron Therapeutics Says James Garner To Step Down As CEO And Managing Director